Daré Bioscience, Inc.
DARE
$2.93
-$0.055-1.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -103.52% | -95.83% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -103.52% | -95.83% | -- | -- | -- |
| Cost of Revenue | -34.04% | 0.00% | 0.00% | 30.80% | -28.28% |
| Gross Profit | 27.68% | -98.29% | 89.60% | 6.40% | 34.30% |
| SG&A Expenses | -32.45% | -24.31% | -16.18% | -19.98% | -8.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.46% | -49.74% | -17.88% | -28.04% | -58.23% |
| Operating Income | -8.38% | 44.25% | 18.13% | 28.15% | 69.37% |
| Income Before Tax | -8.87% | 43.34% | 247.35% | 16.00% | 68.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.87% | 43.34% | 247.35% | 16.00% | 68.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.87% | 43.34% | 247.35% | 16.00% | 68.28% |
| EBIT | -8.38% | 44.25% | 18.13% | 28.15% | 69.37% |
| EBITDA | -8.47% | 44.30% | 18.22% | 28.20% | 69.41% |
| EPS Basic | 0.95% | 49.63% | 226.13% | 28.53% | 70.42% |
| Normalized Basic EPS | -14.37% | 49.62% | 226.12% | 28.53% | 71.60% |
| EPS Diluted | 1.06% | 49.63% | 224.59% | 28.53% | 70.26% |
| Normalized Diluted EPS | -14.37% | 49.62% | 225.16% | 28.53% | 71.60% |
| Average Basic Shares Outstanding | 9.92% | 12.48% | 16.82% | 17.54% | 7.25% |
| Average Diluted Shares Outstanding | 9.92% | 12.48% | 17.72% | 17.54% | 7.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |